Our Pipeline
- Our lead product, CAY001, was designed to address the causes of preventable death from hemorrhage:
- CAY001 reaches non-compressible injury sites via systemic administration.
- CAY001 enables rapid hemostatic control.
- CAY001 currently is in development for the acute treatment of major hemorrhage, including postpartum hemorrhage, traumatic injury, surgical bleeding, gastrointestinal hemorrhage, and bleeding associated with irreversible platelet inhibitors, such as Plavix® (clopidogrel).
- CAY002 is a discovery-stage, novel composition designed for inherited bleeding disorders.
Plavix is a registered trademark of sanofi-aventis